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ABSTRACT 
The objective of this thesis was to characterize the burden of cardiovascular diseases in 
patients with dementia, their treatment and association with survival. Further, we aimed to 
explore whether cardiac structure in young adults can affect the aging brain. We performed 5 
observational cohort studies, based on patients registered in the Swedish Dementia Registry 
(Papers I-IV) and participants in a population-based study Coronary Artery Risk 
Development in Young Adults (Paper V).  
The results can be summarized as follows:  
(I) Seventy per cent of patients with dementia are prescribed cardiovascular drugs. 
Their use is highest in patients with vascular dementia and lowest in patients with 
Parkinson´s disease dementia.  
(II) Patients with heart failure and dementia constitute an old and under-diagnosed 
population. Heart failure with preserved ejection fraction is the most common 
type of heart failure and vascular dementia the most frequent dementia disorder. 
(III) The most common chronic cardiovascular disease in patients with dementia is 
ischemic heart disease (23% of patients are affected), followed by cerebrovascular 
diseases (20% of patients) and atrial fibrillation (19% of patients). The occurrence 
and prognostic significant of chronic cardiovascular diseases differs in specific 
dementia disorders.  
(IV) Twenty one per cent of patients with dementia are managed invasively for acute 
myocardial infarction. The use of invasive procedures is associated with lower 
age and higher cognitive status. This study suggests that the invasive management 
of myocardial infarction has a benefit for survival of patients with dementia.   
(V) Higher left atrial volume in young adulthood is associated with lower white 
matter integrity in mid-life. This study suggests that improvement of cardiac 
function in young adults may benefit the aging brain.  
 
 
 
 
  
LIST OF SCIENTIFIC PAPERS 
I. Cermakova P, Fereshtehnejad SM, Johnell K, Winblad B, Eriksdotter M, 
Religa D. Cardiovascular medication burden in dementia disorders: a 
nationwide study of 19,743 dementia patients in the Swedish Dementia 
Registry.  
Alzheimer's Research & Therapy 2014, 16;6(3):34 
 
II. Cermakova P, Lund LH, Fereshtehnejad SM, Johnell K, Winblad B, 
Dahlström U, Eriksdotter M, Religa D. Heart failure and dementia: survival in 
relation to types of heart failure and different dementia disorders.  
European Journal of Heart Failure 2015, 17(6):612-9 
 
III. Cermakova P, Johnell K, Fastbom J, Garcia-Ptacek S, Lund LH, Winblad B, 
Eriksdotter M, Religa D. Cardiovascular diseases in ~30,000 patients in the 
Swedish Dementia Registry.  
Journal of Alzheimer´s Disease 2015, 48(4):949-58 
 
IV. Cermakova P, Szummer K, Johnell K, Fastbom J, Winblad B, Eriksdotter M, 
Religa D. Management of acute myocardial infarction in patients with 
dementia: data from SveDem, the Swedish Dementia Registry.  
Journal of American Director´s Association 2016,  in press 
 
V. Cermakova P, Muller M, Armstrong AC, Religa D, Bryan NR, Lima JA, 
Launer LJ. Cardiac parameters in young adults and their brain health in mid-
life: CARDIA Brain MRI Sub-study. 
Manuscript 
  
LIST OF SCIENTIFIC PAPERS NOT INCLUDED IN THE 
THESIS 
I. Garcia-Ptacek S, Faxén-Irving G, Cermakova P, Eriksdotter M, Religa D. 
Body mass index in dementia. 
European Journal of Clinical Nutrition 2014, 8(11):1204-9  
 
II. Fereshtehnejad SM, Damangir S, Cermakova P, Aarsland D, Eriksdotter M, 
Religa D. Comorbidity profile in dementia with Lewy bodies versus 
Alzheimer's disease: a linkage study between the Swedish Dementia Registry 
and the Swedish National Patient Registry. 
Alzheimer's Research & Therapy 2014, 6(5-8):65  
 
III. Cermakova P, Eriksdotter M, Lund LH, Winblad B, Religa P, Religa D. 
Heart failure and Alzheimer's disease. 
Journal of Internal Medicine 2015, 277(4):406-25 
 
IV. Religa D, Fereshtehnejad SM, Cermakova P, Edlund AK, Garcia-Ptacek S, 
Granqvist N, Hallbäck A, Kåwe K, Farahmand B, Kilander L, Mattsson UB, 
Nägga K, Nordström P, Wijk H, Wimo A, Winblad B, Eriksdotter M. 
SveDem, the Swedish Dementia Registry - a tool for improving the quality of 
diagnostics, treatment and care of dementia patients in clinical practice.  
PLoS One 2015, 10(2):e0116538  
 
V. Lovas J, Fereshtehnejad SM, Cermakova P, Lundberg C, Johansson B, 
Johansson K, Winblad B, Eriksdotter M, Religa D. Assessment and Reporting 
of Driving Fitness in Patients with Dementia in Clinical Practice: Data from 
SveDem, the Swedish Dementia Registry.  
Journal of Alzheimer´s Disease 2016, 5;53(2):631-8 
 
VI. Enache D, Fereshtehnejad SM, Kåreholt I, Cermakova P, Garcia-Ptacek S, 
Johnell K, Religa D, Jelic V, Winblad B, Ballard C, Aarsland D, Fastbom J, 
Eriksdotter M. Antidepressants and mortality risk in a dementia cohort - data 
from SveDem, the Swedish Dementia Registry.  
Acta Psychiatrica Scandinavica 2016, 134(5):430-440 
 
VII. Garcia-Ptacek S, Kåreholt I, Cermakova P, Rizzuto D, Religa D, Eriksdotter 
M. Causes of death from death certificates in patients with dementia: a cohort 
from the Swedish Dementia Registry.  
Journal of the American Geriatrics Society 2016, in press 
 
VIII. Subic A, Cermakova P, Norrving B, Winblad B, von Euler M, Kramberger 
MG, Eriksdotter M, Garcia-Ptacek S. Management of acute ischemic stroke 
in patients with dementia.  
Journal of Internal Medicine 2016, in press 
 
  
CONTENTS 
1 INTRODUCTION ........................................................................................................ 1 
 1.1 Dementia disorders.................................................................................................... 2 
       1.1.1 Alzheimer´s disease ........................................................................................ 2 
       1.1.2 Vascular dementia ............................................................................................ 3 
       1.1.3 Lewy body dementias ...................................................................................... 4 
       1.1.4 Frontotemporal dementia ................................................................................. 6 
 1.2 Vascular risk factors for dementia ............................................................................ 7 
 1.3 Heart failure ............................................................................................................... 8 
 1.4 Cardiovascular comorbidities of patients with dementia ....................................... 10 
 1.5 Treatment of cardiovascular disease in patients with dementia ............................ 11 
 1.6 Management of acute myocardial infarction in patients with dementia ................ 12 
2 AIMS ............................................................................................................................. 14 
3 METHODS .................................................................................................................. 15 
 3.1 Data .......................................................................................................................... 15 
 3.2 Definitions ............................................................................................................... 16 
 3.3 Statistical analysis ................................................................................................... 17 
4 ETHICAL CONSIDERATIONS ............................................................................. 20 
5 RESULTS AND DISCUSSION ................................................................................ 21 
 5.1 Cardiovascular medication in patients with dementia (Paper I) ............................ 21 
 5.2 Characteristics of patients with heart failure and dementia (Paper II) .................. 24 
 5.3 Cardiovascular comorbidities of patients with dementia (Paper III) ..................... 26 
 5.4 Management of myocardial infarction in patients with dementia (Paper IV) ....... 31 
 5.5 Cardiac parameters in young adults and their brain in mid-life (Paper V) ........... 34 
6 METHODOLOGICAL CONSIDERATIONS ....................................................... 37 
 6.1 Selection bias ........................................................................................................... 37 
 6.2 Misclassification and confounding ......................................................................... 38 
7 FUTURE PERSPECTIVES ...................................................................................... 39 
8 ACKNOWLEDGEMENTS ...................................................................................... 40 
9 REFERENCES............................................................................................................ 41 
  
  
LIST OF ABBREVIATIONS 
ACEI Angiotensin-converting enzyme inhibitor 
AD Alzheimer´s disease 
CARDIA Coronary Artery Risk Development in Young Adults 
CI Confidence interval 
CVD Cardiovascular disease 
DLB Dementia with Lewy bodies 
DTI Diffusion tensor imaging 
FUS Fused-in-sarcoma   
FTD Frontotemporal dementia 
HFPEF Heart failure with preserved ejection fraction 
HFREF Heart failure with reduced ejection fraction 
HR Hazard ratio 
ICD International Classification of Diseases 
MAPT Microtubule-associated protein tau 
MMSE Mini Mental State Examination 
MRI Magnetic Resonance Imaging 
NSTEMI Myocardial infarction without ST-elevation 
OR Odds ratio 
PCI Percutaneous coronary intervention 
PDD Parkinson´s disease dementia 
SD Standard deviation 
STEMI Myocardial infarction with ST-elevation 
RAAS Renin-angiotensin-aldosterone system 
RiksSvikt Swedish Heart Failure Registry 
SveDem Swedish Dementia Registry 
TDP-43 TAR DNA-binding protein with molecular weight 43 kDa 
VRF Vascular risk factor 
 

 1 
 
1 INTRODUCTION 
 
The remarkable increase in life expectancy in developed countries is considered an 
accomplishment of the 20th century1. Resulting from better hygiene, the use of antibiotics and 
vaccinations, the risk of dying from infectious diseases has decreased substantially. Child and 
maternal mortality have rapidly dropped and people now reach mature age, when they face 
higher risks of chronic age-related conditions, such as cardiovascular disease (CVD) and 
dementia. Thanks to advances in medical care, many older people now survive several 
diseases that previously were fatal. As a consequence of this, older people are now able to 
tolerate a certain degree of disability, which we may understand as any health loss, other than 
death2.  
CVD, including a wide range of conditions, such as ischemic heart disease, cerebrovascular 
diseases, heart failure or cardiac arrhythmias, are leading causes of death worldwide3. Given 
major advancements in their prevention and therapy, the risk of dying from CVD was shifted 
to older ages. As opposed to declining trends of disability caused by CVD4, a looming 
epidemic of dementia, the main cause of disability of the elderly patients, has brought 
concern5. Dementia is a heterogeneous syndrome constituted of several types (Table 1) and is 
characterized by progressive impairment in cognition that leads to patients´ dependency on 
caregivers. The prevalence of dementia increases with age, affecting 5% of the population 
over 65 years, and up to 50% of persons at the age of 90 years6. In 2015, almost 47 million 
people worldwide were estimated to be affected by dementia and this number is projected to 
reach 75 million by 20307.  
 
Table 1 Types of dementia disorders8-15 
Dementia disorder Estimated proportion of all dementia cases 
Alzheimer´s disease 50-70% 
Vascular dementia 15% 
Lewy body dementias 
3-10% in population-based studies 
20% in clinic-based studies 
Frontotemporal dementia 
1% among patients ≥ 68 years 
3-26% among patients ≤ 65 years 
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1.1 DEMENTIA DISORDERS 
1.1.1 Alzheimer´s disease 
 
Alzheimer´s disease (AD) is the most common cause of dementia and accounts for two thirds 
of all cases9. Typically, AD starts with difficulties recalling recent events. As the disease 
progresses, patients start having problems with managing complex tasks, orientation and 
recognizing faces. Poor judgement, difficulties with language and behavioral and psychiatric 
symptoms also accompany AD (Figure 1)9. In atypical cases of AD, visual, executive and 
language problems are more pronounced and occur earlier than memory problems16.  
Figure 1 Clinical manifestation of AD9 
 
AD usually affects people older than 65 years (late-onset AD), has a slow, progressive 
character and heterogeneous etiology. Several psychological, social and vascular risk factors 
for AD have been identified. The vascular risk factors are discussed in Chapter 1.2. The most 
important genetic risk factor is the presence of the ε4 allele of the gene for apolipoprotein E 
(APOE ε4 )17. In about 10% of patients, AD appears before the age of 65 (early-onset AD), 
often presents with atypical symptoms and is largely genetically determined18.  
Pathological hallmarks of AD include extracellular plaques of amyloid beta protein and 
intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein, together 
with degeneration of neurons and synapses. The amyloid cascade hypothesis postulated that 
amyloid deposition is the primary event that leads to the formation of tangles, degeneration of 
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neurons and dementia19. This hypothesis has been challenged by findings suggesting the 
occurrence of tangles before amyloid plaques, a correlation of cognitive decline with tangles, 
but not plaques, and an increase in amyloid as a consequence of neuronal damage caused by 
another process20-22. Moreover, amyloid depositions are frequent findings in the brains of 
persons who never had symptoms of dementia23. 
Most people with AD also have other pathologies in the brain, such as cerebrovascular 
lesions as well as findings primarily related to Lewy body dementias or frontotemporal 
dementia (FTD). They may contribute to the occurrence of the amyloid plaques and tangles 
or have an additive effect on them, lowering the threshold for the clinical presentation of 
dementia24-26. Several other hypotheses for AD have also been suggested, such as imbalance 
of the inflammatory system, energy metabolism, oxidative stress and dysregulation of the cell 
cycle8,27.  
The pathological processes in the brain may start up to decades before cognition declines and 
are reflected by biomarkers acquired from the cerebrospinal fluid and by neuroimaging 
methods28. The first detectable biomarkers are those of amyloid deposition and are followed 
by markers of neurodegeneration related to tau pathology, before cognitive impairment 
appears29. However, it is acknowledged that recognition of the earliest AD pathology is 
beneath the detection threshold of all currently used AD biomarkers29. Recent advances in 
sensitive magnetic resonance imaging (MRI) techniques are promising in detecting earlier 
stages of brain pathology. For example, diffusion tensor imaging (DTI) may reveal early 
disruption of integrity of white matter, years before other biomarkers become apparent30,31. 
Until now, there have been no disease-modifying treatments for AD and patients die within 
4-7 years after the diagnosis32-34. Knowledge on the dysfunction of neurotransmitters led to 
the development of drugs that improve cognition, behavioral and functional status35. As 
degeneration of cholinergic neurons is an early event in AD, acetylcholinesterase inhibitors 
are the main therapy35. Co-administration of memantine, an N-methyl-D-aspartate receptor 
antagonist, further slows down cognitive and functional decline in patients with moderate-to-
severe AD35,36.    
1.1.2 Vascular dementia 
 
Vascular dementia is the second most common type of dementia disorder and accounts for 
around 15% of dementia cases15. It is characterized by cognitive impairment due to 
cerebrovascular lesions that vary in their number, location, form and size (Figure 2). 
Frequently present lesions in subcortical areas lead to deficits in attention, information 
 4 
 
processing and executive functions15. Memory, language and praxis are variably affected and 
non-cognitive symptoms, in particular depression and apathy, often occur15,37. There is 
currently no treatment for vascular dementia. Mortality is higher than in AD, as it is estimated 
that patients die after 3-5 years since the diagnosis15,38. 
 
 
 
 
 
 
 
 
Figure 2 Types of vascular dementia due to different cerebrovascular lesions15 
 
Individuals with vascular dementia are often afflicted with AD pathology and are then 
diagnosed with mixed dementia39. Mixed dementia is usually considered the third most 
common type of dementia, moving up to first or second rank among the oldest patients40. The 
threshold for distinguishing between AD and vascular dementia is unclear and depends on 
diagnostic traditions and resources41,42. Initially, mixed dementia was diagnosed in the 
presence of AD pathology and large infarcts. Later, the importance of lacunes and white 
matter lesions for cognitive impairment has become apparent. Thus, the diagnosis of mixed 
dementia covers a wide spectrum of combinations between AD pathology and vascular 
lesions39-41. 
1.1.3 Lewy body dementias 
 
Lewy body dementias is an umbrella term for two clinical entities: dementia with Lewy 
bodies (DLB) and Parkinson´s disease dementia (PDD)11. It is characterized by the presence 
of dementia and motor symptoms of parkinsonism, such as tremor, rigidity and bradykinesia 
(Figure 3). The neuropathological hallmarks of Lewy body dementias are Lewy bodies and 
Lewy neurites that contain inclusions of alpha-synuclein, accompanied by degeneration of 
neurons43,44.   
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Patients with DLB present with fluctuating cognitive impairment, recurrent visual 
hallucinations and rapid eye movement sleep behavior disorder. Parkinsonism occurs after or 
at the time of the manifestation of dementia in 60-90% of patients45. PDD is a clinical entity, 
in which dementia developed in an established Parkinson´s disease, at least 1 year after the 
onset of the motor symptoms46. The point-prevalence of dementia in Parkinson´s disease is 
25%47. Whether the patients progress into dementia depends on their age and the duration of 
the disease. Ten years after the diagnosis of Parkinson´s disease, the risk of having dementia 
is 50%11. Once dementia manifests in Parkinson´s disease, no clinical difference can 
distinguish it from DLB.  
Lewy bodies are found in several central and peripheral autonomic centers, leading to failure 
of parasympathetic and sympathetic nervous system48. Frequent manifestation of sympathetic 
dysfunction is orthostatic hypotension, present in 80% of patients with Lewy body dementias. 
Persistent orthostatic hypotension is a predictor of the survival of the patient49. 
Acetylcholinesterase inhibitors moderately benefit the patients with Lewy body dementias. 
Mortality is higher than in AD; the patients die on average 4 years after the diagnosis of 
dementia38,50. 
Figure 3 Features of Lewy body dementias11 
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1.1.4 Frontotemporal dementia 
 
Frontotemporal dementia (FTD), the leading type of early-onset dementia, is characterized by 
neurodegeneration in frontal and temporal lobes. It can be classified as behavioral variant 
FTD, which presents with deficits in behavior and executive functions, or as primary 
progressive aphasia, where the main symptoms are problems with language (Figure 4)13,51. 
Features of motor neuron disease may occur in up to 40% of patients with FTD. Three main 
neuropathological hallmarks have been identified: microtubule-associated protein tau 
(MAPT), the TAR DNA-binding protein with molecular weight 43 kDa (TDP-43) and the 
fused-in-sarcoma (FUS) protein52. Family history of the disease is reported in up to 40% of 
FTD patients, with 10% of cases having a clear autosomal dominant inheritance13,53. No 
approved disease-modifying drugs are available for the treatment of FTD and patients are 
estimated to survive 2-5 years after the clinical diagnosis13. 
 
Figure 4 Characteristics of frontotemporal dementia13  
MAPT, microtubule-associated protein tau; TDP-43, TAR DNA-binding protein with 
molecular weight 43 kDa; FUS, fused-in-sarcoma   
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1.2 VASCULAR RISK FACTORS FOR DEMENTIA 
It has been well established that traditional vascular risk factors (VRFs), such as 
hypertension, hypercholesterolaemia, diabetes mellitus, smoking, sedentary behavior and 
obesity, increase the risk of developing cognitive decline and dementia54. These associations 
are strongest when multiple VRFs are present in mid-life or last from early adulthood and are 
left untreated55-58. The influence of VRFs in late-life on the occurrence of dementia is less 
certain, as many studies report inverse associations59-61, probably reflecting that the levels of 
several VRFs decrease some years before the diagnosis of dementia.   
The effect of VRFs on the development of cognitive decline and dementia is mainly 
explained by the presence of atherosclerosis, arteriolosclerosis and vascular stiffness (Figure 
5)56,62. The associations between VRFs and dementia are largely mediated by mixed 
cerebrovascular and neurodegenerative lesions56,62, which emerge through several 
mechanisms including insufficient perfusion, hypoxia, inflammation or oxidative stress56,62. 
Each VRF may also uniquely impact the brain. Hypertension may cause cerebral 
hypoperfusion due to impaired cerebral autoregulation63. Diabetes mellitus can lead to 
neuronal damage as a result of accumulated advanced glycation end-products64. Endocrine, 
inflammatory and thrombotic functions of adipokines may explain the link between obesity 
and dementia65.  
Furthermore, an established CVD, as a consequence of the exposure to VRFs, may directly 
contribute to the trajectory towards dementia. Atrial fibrillation, the most common type of 
arrhythmia, has been found associated with a risk of cognitive impairment and dementia, 
likely due to embolism, brain hypoperfusion due to irregular heart beat and reduced cardiac 
output66. Some epidemiological studies suggest an association of myocardial infarction with a 
higher risk of dementia67,68, however, results are inconsistent69,70. The relationship between 
heart failure and dementia is discussed in the next chapter.  
Recent studies, using sensitive MRI techniques, suggest that VRFs may affect the brain 
already in mid-life. Hypertension was found associated with impairment in white matter 
integrity, lower cerebral blood flow and cerebrovascular reactivity in individuals at the age of 
5071,72. In the same cohort, high body mass index and smoking were associated with lower 
cerebral blood flow. Further, moving against the life course, high systolic blood pressure was 
found associated with impaired white matter integrity in individuals already at the mean age 
39 years31. 
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Observational studies implicate a causal relationship between vascular pathology and AD as 
well as vascular dementia. There is less evidence that cerebrovascular pathology contributes 
substantially to the occurrence of Lewy body dementias and FTD. Traditional VRFs 
including blood pressure, diabetes mellitus and cholesterol have not been found associated 
with a risk of Parkinson´s disease73. Interestingly, smoking seems to be a protective factor 
against Parkinson´s disease74. However, concomitant cerebrovascular pathology may modify 
the course of Parkinson´s disease and contribute to the development of dementia75-79. One 
study indicated that diabetes mellitus may increase the risk of FTD80, but this finding has not 
been replicated81. 
Figure 5 Relationship between vascular risk factors and dementia82 
 
1.3 HEART FAILURE 
 
The burden of VRFs and CVD may ultimately lead to heart failure, when the heart is unable 
to pump blood in order to meet the metabolic needs of the body. Heart failure is a syndrome 
caused by an abnormality in a structure or a function of the heart, clinically presenting with 
breathlessness, ankle swelling and fatigue. Its prevalence in the adult population is 2% and is 
rising to more than 10% among people older than 70 years83. In the United States, the burden 
of heart failure is highest among African Americans who present with symptoms at younger 
age. One in 100 African Americans develops heart failure before the age of 50, which is 20 
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times higher than the incidence in Caucasian populations84. Approximately half of patients 
with heart failure have left ventricular ejection fraction below 40% (heart failure with reduced 
ejection fraction, HFREF), while the rest is affected by heart failure with preserved ejection 
fraction (HFPEF).  
HFREF is characterized by systolic dysfunction that emerges as a consequence of cardiac 
remodeling following loss of cardiomyocytes, caused by for example myocardial infarction85. 
Activation of the renin-angiotensin-aldosterone system (RAAS) accompanies HFREF and its 
inhibition is the main treatment strategy for HFREF83. Angiotensin-converting enzyme 
inhibitors (ACEIs) and beta blockers are recommended for all patients with HFREF83. In case 
of intolerance to ACEIs, angiotensin-receptor blockers should be prescribed83. In addition, 
mineralocorticoid receptor antagonists are recommended for patients with left ventricular 
ejection fraction lower than 35%83.  
On the contrary, HFPEF is driven by aging and comorbidities such as obesity, diabetes 
mellitus, hypertension and atrial fibrillation85. These induce a systemic inflammatory state 
and microvascular endothelial dysfunction that trigger cardiac remodeling, leading to 
diastolic dysfunction85. No medicines have been shown in clinical trials to improve mortality 
in patients with HFPEF83. The proportion of HFREF among patients with heart failure has 
been declining and HFPEF, now increasingly recognized as equally serious as HFREF, is 
projected to become the predominant type in the future83,86,87.  
Despite shared VRFs, it is evident that heart failure may increase the risk of dementia due to 
insufficient cardiac output, leading to decreased cerebral perfusion (Figure 6)87. Moreover, 
systemic inflammation and endothelial dysfunction driven by comorbidities may put the brain 
at risk for structural abnormality87. Given the expanding proportion of older individuals, it is 
expected that more people will be affected with both dementia and heart failure in the future. 
It is unclear how this will affect their prognosis.   
Heart failure is preceded by a long pre-clinical period when subtle cardiac dysfunction is 
frequently present without any clinical symptoms88. Markers of subclinical cardiac 
dysfunction, such as decreased left ventricular ejection fraction, increased left atrial volume 
or higher left ventricular mass are precursors of incident heart failure88-91 . These 
parameters have been found associated with preclinical markers of dementia assessed by 
MRI, such as loss of brain volume, ischemic lesions and impaired integrity of the white 
matter92,93. Recent studies indicate that antecedents of heart failure occur already in the 
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young adulthood94. From this follows a hypothesis that subclinical cardiac dysfunction may 
affect aging of the brain as early as in young adulthood.  
 
 
 
Figure 6 The complex relationship between heart failure and dementia87 
 
1.4 CARDIOVASCULAR COMORBIDITIES OF PATIENTS WITH DEMENTIA 
 
When CVDs occur in patients with dementia, they no longer function as risk factors, but 
accompany dementia as comorbidities and may lead to a greater risk of death and a worse 
functional status. The prevalence of comorbidities in patients with dementia compared to 
dementia-free individuals is a matter of debate95-102. The often reported lower burden of 
comorbidities in dementia can be a true finding, may reflect differences in survival (the sicker 
patients may have died before they developed dementia) or may be due to underdiagnosing of 
comorbidities. Patients with dementia are not able to sufficiently express discomfort; 
moreover, physicians may lose sight of other conditions or have low diagnostic ambitions 
when facing a person with dementia.   
There are indications of lower occurrence of myocardial infarction after the diagnosis of 
dementia70,103. Even though underdiagnosing is the most plausible explanation, it cannot be 
excluded that this is a true finding. Nordström et al. showed that the use of 
acetylcholinesterase inhibitors, that may have cardioprotective properties, was associated 
with a lower incidence of myocardial infarction in patients with dementia103. Moreover, the 
levels of VRFs, such as blood pressure, cholesterol and body mass index drop in pre-clinical 
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stages of dementia59-61, suggesting that patients with dementia may truly be at a lower risk of 
acute myocardial infarction.    
Conversely, patients with dementia, in particular at more advanced stages, are at a higher risk 
of developing strokes104. Compared to dementia-free individuals, stroke is almost three times 
more likely to occur in patients with mild dementia and up to seven times more in those with 
severe dementia105,106. This high risk can be explained by cerebrovascular lesions that are 
already present in patients with dementia and are associated with a higher risk of subsequent 
strokes106-108. Moreover, antipsychotic drugs, used to treat behavioral symptoms in dementia, 
may cause strokes as well109. 
Several studies suggested a lower occurrence of diabetes mellitus, cerebrovascular disease 
and ischemic heart disease in patients with Parkinson´s disease75,110,111. This may be 
explained by a lower severity of atherosclerosis due to non-smoking as well as the failure of 
the sympathetic nervous system, which possibly plays a role in the genesis of CVD110. 
However, conflicting evidence exists76 as well as indications of a higher occurrence of heart 
failure in Parkinson´s disease75, likely caused by medication112. Data on comorbid CVD in 
patients with diagnosed Lewy body dementias and FTD are scarce, due to a lack of large 
patient cohorts.   
 
1.5 TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH 
DEMENTIA 
 
Patients with dementia are treated less intensively for CVDs, including ischemic heart 
disease, cerebrovascular disease, atrial fibrillation and heart failure113-117. The potential under-
treatment of CVDs occurs most often in patients with severe dementia and among those 
living in nursing homes118. Whether this lower intensity can be considered as under-treatment 
requires more knowledge about what is the appropriate management of CVDs in patients 
with dementia. Ideally, the adequate management of CVDs in dementia should slow down 
the progression of cognitive and functional decline and reduce the risk of death. Conversely, 
under- or overtreatment may do the opposite. There are no specific guidelines for treating 
CVDs in patients with dementia, likely because of lacking evidence due to their exclusion 
from clinical trials119,120.  
The reasons for potential under-treatment of CVDs in dementia may be multiple (Figure 7). 
Patients with dementia are more likely to be physically frail, face more severe adverse effects 
from drug interactions and are at a higher risk of death121-123. Moreover, they often suffer 
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from orthostatic hypotension, in particular those with Lewy body dementias, which 
complicates the management of CVDs124-126. Patients with advanced cognitive impairment 
and those who live alone have problems with administration and adherence to drug 
regimens127,128. We can deduce that the results from clinical studies may not be simply 
conveyed and generalized to patients with dementia, who probably constitute a special patient 
population123.  
Several other factors may hinder receiving the optimal treatment for CVD. Patients with 
dementia may have worse access to health care, due to their dependency on caregivers and 
cognitive impairment. Moreover, dementia can be perceived as a stigma129 and together with 
lower socioeconomic status, associated with dementia130, may influence the attitude of 
physicians when deciding about the treatment.  
 
Figure 7 Suggestions of mechanisms leading to less optimal treatment of CVD in patients 
with dementia 
 
1.6 MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS 
WITH DEMENTIA 
 
Acute myocardial infarction is characterized by irreversible cell death in myocardium due to 
insufficient blood supply. According to echocardiographic findings, it presents as myocardial 
infarction with ST-elevation (STEMI), or myocardial infarction without ST-elevation 
(NSTEMI)131,132. NSTEMI accounts for 75% of cases of acute myocardial infarction in 
octogenarians133,134. The incidence of acute myocardial infarction, in particular of STEMI, 
has been declining135
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Mortality rates from acute myocardial infarction have significantly dropped over the past 
decades, largely due to the use of invasive procedures such as coronary angiography and 
revascularization with percutaneous coronary intervention (PCI)135. An early invasive 
strategy for STEMI patients and assessment for the invasive management in patients with 
NSTEMI are recommended131,132. This has been successfully implemented, especially in 
younger individuals and men131-133.  
Several reasons hinder the use of invasive procedures in the treatment of acute myocardial 
infarction in older patients. The most typical symptom, chest pain, is reported only in 40% of 
octogenarians132, who usually experience atypical symptoms, such as dyspnea, nausea or 
syncope131. Moreover, prompt arrival to the hospital is necessary to perform 
revascularization, and older individuals, especially women, frequently have pre-hospital 
delays131.  
Dementia is associated with a higher mortality from acute myocardial infarction and is also a 
barrier for receiving coronary angiography and PCI113,136-138. As the benefits of the invasive 
management are highly uncertain in patients with dementia, clinicians face difficult 
decisions113,136-138. One study, however, found that the use of PCI in patients with dementia 
was associated with lower in-hospital mortality136, indicating that individuals with dementia 
may in fact benefit from it.   
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2 AIMS 
The objective of this thesis is to characterize the burden of CVD in patients with dementia, 
their treatment and impact on survival, with an emphasis on heart failure and acute 
myocardial infarction. Further aim is to study whether cardiac parameters in young adulthood 
may influence brain structure in mid-life.  
Specifically, we aimed to study 
- factors associated with prescription of cardiovascular drugs in patients with dementia 
(Paper I)  
- clinical characteristics of patients with heart failure and dementia and their mortality 
(Paper II)  
- frequency of chronic CVDs in patients with dementia and their association with 
mortality (Paper III)  
- proportion of patients with dementia who were managed invasively for acute 
myocardial infarction; and whether this was associated with longer survival (Paper 
IV) 
- associations of echocardiograhic parameters in young adulthood with brain MRI 
markers in mid-life (Paper V)  
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3 METHODS 
 
We performed 5 observational cohort studies. Papers I-IV are based on patients registered in 
the Swedish Dementia Registry (SveDem). Their information has been linked with data from 
the Swedish Heart Failure Registry (RiksSvikt), the Swedish Patient Register, the Swedish 
Prescribed Drug Register and the Swedish Population Register. Paper V is based on data 
from an American population-based study Coronary Artery Risk Development in Young 
Adults (CARDIA).  
3.1 DATA 
 
SveDem is a Swedish national registry that aims to monitor and ensure the quality of the 
diagnostic work-up, treatment and care of patients with dementia in Sweden and was 
previously described in detail139. Briefly, it was established in 2007 with the aim to register 
all individuals at the time of dementia diagnosis and follow them yearly. In 2013, it included 
36 383 registrations of patients who were newly diagnosed by physicians in memory clinics 
(65% of patients) or primary care (35% of patients). Patients are diagnosed with one of 8 
dementia disorders (Figure 8). Information about age, gender, living conditions, results from 
the Mini Mental State Examination (MMSE), diagnostic procedures and treatment is 
recorded.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Distribution of dementia disorders in SveDem 
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RiksSvikt is a Swedish national register that was established in 2003 with the goal to monitor 
and improve the care of patients with heart failure in Sweden140. In 2013, it included 55 313 
patients who were registered in a hospital (93% of patients) or in primary care (7% of 
patients). Information about demographic data, medication, duration, type and severity of 
heart failure is registered.  
 
The Swedish Patient Register covers in-patient and out-patient care encounters in Sweden141. 
One main diagnosis and up to 21 additional diagnoses are registered with an International 
Classification of Diseases (ICD) code together with demographics, administrative 
information and surgical procedures. The Swedish Prescribed Drug Register contains 
information on all dispensed prescriptions at Swedish pharmacies to the entire Swedish 
population142. Drugs are coded according to the Anatomical Therapeutic Chemical 
Classification system. 
 
CARDIA was established in 1985 in 4 centers in the United States (Birmingham, Chicago, 
Minneapolis and Oakland) with the aim to examine the trajectories of CVD starting in young 
adulthood143. The original cohort consisted of 5 115 persons (age 18-30 years, 52% African 
Americans, 55% women). At the 5th follow-up year, the study participants received an 
ultrasound examination of the heart144. In 2010, 72% of the surviving cohort underwent the 
25th follow-up exam. From those, 719 persons participated in the brain MRI examination 
(CARDIA Brain MRI Sub-study)72.  
 
3.2 DEFINITIONS 
 
In Papers I-IV, dementia was diagnosed according to ICD 10145. In addition, McKeith criteria 
were used for DLB146, Lund-Manchester criteria for FTD147 and Movement Disorder Society 
Task Force criteria for PDD46. Unspecified dementia is registered if the dementia etiology is 
unknown or if the diagnostic tests have not been performed. Other dementia types include 
less frequent dementia disorders, such as alcohol-related dementia.  
In Paper I, we studied prescription of cardiovascular drugs in patients registered in SveDem. 
These include antihypertensive drugs, anticoagulants, lipid-lowering drugs, anti-diabetics and 
anti-angina medication. The information is based on medical records, thus was obtained 
during medical examination, directly from patients or indirectly from caregivers.  
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In Paper II, we studied patients with heart failure and dementia, registered in SveDem and 
RiksSvikt. We divided patients into 3 groups according to type of heart failure: HFPEF 
(ejection fraction ≥ 40%), HFREF (ejection fraction < 40%) and heart failure with missing 
ejection fraction, when the value of ejection fraction was absent in RiksSvikt. Further, we 
divided patients into 4 groups based on type of dementia disorder: AD, mixed dementia, 
vascular dementia and other dementia disorders.   
In Paper III, we characterized chronic CVDs based on records in the Swedish National 
Patient Register from 2000 until 2012. Following ICD codes were used: ischemic heart 
disease (I20-I25), atrial fibrillation and flutter (I48), heart failure (I50), cerebrovascular 
diseases (I60-I69) and diabetes mellitus (E10-E13). 
In Paper IV, we identified patients who suffered an acute myocardial infarction after the 
diagnosis of dementia by the following codes in the Swedish National Patient Register: 
STEMI (I21.0-I21.3), NSTEMI (I21.4) and unspecified acute myocardial infarction (I21.9). 
Invasive management was defined as coronary angiography (AF037) and percutaneous 
coronary intervention (FNG02 or FNG05), occurring during the same hospitalization. 
Comorbidity was defined by a sum of 9 diseases (shock, diabetes mellitus, heart failure, 
cancer, cerebrovascular disease, pulmonary edema, acute renal disease, chronic renal disease, 
cardiac dysrhythmia)148 or total number of drugs149.  
In Paper V, cardiac parameters were obtained by a two-dimensional and guided M-mode 
echocardiography144. Parameters of interest were left ventricular ejection fraction, left atrial 
volume and left ventricular mass. Markers of brain health obtained by MRI were white matter 
fractional anisotropy (a measure of white matter integrity estimated from DTI), volumes of 
normal brain tissue (total brain, gray matter and white matter) and volume of abnormal white 
matter, including tissue damaged due to ischemia, demyelination and inflammation. The 
volume of abnormal white matter was classified as none (0 cm3), little (≤ 0.3 cm3) and high 
(> 0.3 cm3). 
 
3.3 STATISTICAL ANALYSIS  
 
The selection of study samples is presented on Figure 9. Briefly, for Paper I we selected 
19 743 patients registered in SveDem between 2007 and 2012, who had information on the 
use of cardiovascular medication. Paper II included patients registered in SveDem and 
RiksSvikt (n=775). Patients registered in SveDem between 2007 and 2012 were the basis for 
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Paper III (n=29 630) and those who suffered acute myocardial infarction after the dementia 
diagnosis were included in Paper IV (n=525). Participants in CARDIA with data on brain 
MRI and echocardiography were selected for Paper V (n=648).  
All analyses were performed using IBM SPSS Statistics for Windows, Version 22.0. (IBM 
Corp. Armonk, NY). Descriptive data is presented as mean ± standard deviation (SD), 
median (25%; 75%) / interquartile range and frequency (%). To compare characteristics 
between groups, we used an independent sample t-test / 1-way analysis of variance for 
continuous variables with normal distribution, Mann-Whitney U test / Kruskal-Wallis test for 
continuous variables with skewed distribution and chi-squared test / Fisher exact test for 
categorical variables.  
In Paper I, we used binary logistic regression to estimate odds ratios (ORs) with 95% 
confidence intervals (CIs) for associations of patients´ characteristics (age, gender, MMSE, 
living conditions, dementia disorder) with the use of cardiovascular drugs.  
In Paper II, we used multinomial logistic regression to explore associations between type of 
dementia disorders and type of heart failure. We analyzed survival with Kaplan-Meier curves 
and used log rank tests to compare groups. We followed the patients from the date they were 
registered in both SveDem and RiksSvikt until the death or the end of follow-up in October 
2013.  
In Paper III, we performed multinomial logistic regression to estimate OR with 95% CI for 
associations of CVD with dementia disorders, when compared to AD. To study mortality 
associated with CVD, we applied Cox regression to estimate hazard ratio (HR) with 95% CI 
for associations of CVD with all-cause mortality. The patients were followed up from the 
time of dementia diagnosis until their death or the end of the follow-up in October 2013. 
In Paper IV, we applied binary logistic regression to examine the associations of patients´ 
characteristics with the invasive management of myocardial infarction. We assessed survival 
by Kaplan-Meier curves and then used Cox regression to estimate HR with 95% CI for an 
association of the use of the invasive procedures with all-cause mortality. The patients were 
followed-up from the date of myocardial infarction until their death or to December 2012.  
In Paper V, we applied linear regression to investigate associations of cardiac parameters 
with white matter fractional anisotropy, volume of total brain, gray matter and white matter. 
We used logistic regression to assess the associations of the cardiac parameters with 
abnormal white matter volume.  
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Figure 9 Selection of the study samples 
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4 ETHICAL CONSIDERATIONS 
 
Research ethics deals with the concepts of autonomy and personal integrity of the studied 
individuals. Autonomy relates to the right of everyone to make their own decisions. Personal 
integrity comprises privacy, dignity and presupposes respect for other people´s feelings and 
their “right to be forgotten”. Data concerning health is considered sensitive, is protected by 
secrecy and requires ethical vetting. In order to maintain people´s autonomy and personal 
integrity while performing research, an informed consent is usually required.  
 
Papers I-IV were approved by the regional ethical review board in Stockholm. No written 
informed consent was acquired. Patients and their relatives were informed about registrations 
into SveDem and RiksSvikt and had a right to decline participation and have their 
information removed. It needs to be acknowledged that patients with dementia have limited 
ability to decide on their own whether they want to be registered in SveDem due to their low 
cognitive functions. However, according to the principle of justice and equality, everybody 
should be provided appropriate access to participation in research, including underrepresented 
groups and individuals who cannot consent themselves150-152.  
 
Unlike quality registers, there is no possibility to have data removed from Swedish health 
registers (the Swedish Patient Register and Swedish Prescribed Drug Register). The 
advantage of using data from registers is that this is a timely and cost-effective way that does 
not include risks by interventions. To reduce the potential harm of utilizing sensitive personal 
information, data were de-identified and results are presented only on a group level.  
 
For Paper V, all participants in CARDIA provided a written informed consent at each exam 
and institutional review boards from each center annually approve the study. A separate 
approval was given by the institutional review boards of the participating sites and the 
institutional review board covering Intramural Research at the National Institute of Aging. 
Another written consent for the CARDIA MRI Sub-study was obtained.  
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5 RESULTS AND DISCUSSION 
5.1 CARDIOVASCULAR MEDICATION IN PATIENTS WITH DEMENTIA 
(PAPER I) 
 
From 19 743 patients with dementia (58% women, mean age 79 years), 70% (n=13 847) 
were prescribed cardiovascular drugs. Their use was highest in patients with vascular 
dementia (84%) and lowest in frontotemporal dementia (53%, Figure 10). Patients who were 
prescribed cardiovascular drugs were older (80 vs. 77 years; p<0.001), less frequently women 
(56% vs. 64%; p<0.001), had a slightly higher MMSE score (21.4 vs. 21.3; p<0.001) and 
lived less frequently alone (44% vs. 46%; p=0.01).  
Figure 10 Use of cardiovascular drugs in different dementia disorders 
 
In multivariate analysis (Table 2), we found that higher age (OR 1.02; 95 CI 1.01-1.02), male 
gender (OR 1.45; 95% CI 1.34-1.57) and a higher MMSE score (OR 1.02; 95% CI 1.01-
1.03) were associated with the use of cardiovascular drugs. On the other hand, living alone 
was inversely associated with cardiovascular drugs (OR 0.75; 955 CI 0.69-0.81). When 
compared to AD, patients with mixed dementia and vascular dementia had higher odds of 
taking cardiovascular drugs, while the opposite was found for DLB (OR 0.71; 95% CI 0.58-
0.87) and PDD patients (OR 0.31; 95% CI 0.24-0.40).    
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Table 2 Associations of patients´ characteristics with the use of cardiovascular drugs 
 
OR (95% CI) 
Age 1.02 (1.01-1.02)** 
Male gender  1.45 (1.34-1.57)** 
MMSE 1.02 (1.01-1.03)** 
Living alone 0.75 (0.69-0.81)** 
Dementia disorders 
Alzheimer´s disease Reference 
Mixed dementia 1.57 (1.43-1.73)** 
Vascular dementia 2.14 (1.89-2.44)** 
Dementia with Lewy bodies 0.71 (0.58-0.87)** 
Frontotemporal dementia 0.91 (0.71-1.17) 
Parkinson´s disease dementia 0.31 (0.24-0.40)** 
 
MMSE, Mini Mental State Examination; OR, odds ratio; CI, confidence interval 
** p˂0.001 
ORs with 95% CI are derived from binary logistic regression and are estimates for 
associations of clinical characteristics with the use of cardiovascular drugs. All variables 
in this table as well as use of cholinesterase inhibitors, memantine and total number of 
drugs are included in the model. 
 
In Paper I, we studied the use of cardiovascular drugs in SveDem, a Swedish quality register 
of patients with dementia. This information may be viewed as a proxy for cardiovascular 
comorbidity or indicate clinical practice of treating CVD. The frequency of cardiovascular 
drugs among patients with dementia (70%) is slightly higher than in the general population of 
older Swedes (mean age 82 years), from whom 66% use cardiovascular drugs153, but lower 
than in other dementia cohorts154,155. 
In Spain, almost 80% of patients with dementia registered in specialist clinics receive 
cardiovascular drugs, despite having a lower prevalence of CVD compared to Sweden154. In 
Germany, 90% of individuals with dementia are prescribed at least one cardiovascular drug*. 
In Finland, 80% of AD patients are treated with cardiovascular medication155. These 
differences may indicate less aggressive treatment of CVD in patients with dementia in 
Sweden when compared to other countries. 
Three main limitations of this study possibly lead to underestimation of the use of 
cardiovascular drugs in AD. First, no guidelines clearly specify how to deal with 
cerebrovascular pathology that is present in around 50% of AD patients5, causing 
                                                 
*
 Personal communication; the information concerns drugs prescribed by general practitioners and is based on 
Disease Analyzer database  
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inconsistency in the amount of cerebrovascular disease allowed for the diagnosis of AD vs. 
mixed dementia8,156. Second, we excluded patients with unspecified dementia, who have a 
high cardiovascular comorbidity burden, and likely include a high proportion of patients with 
AD. These patients, predominantly registered to SveDem in primary care, may have not 
received a specific dementia diagnosis due to their high age, frailty and thus perceived 
marginal benefits from an extended diagnostic work-up. Third, this study is limited by 
circular reasoning, as patients with more CVD and thus more cardiovascular drugs are more 
likely to be diagnosed with vascular dementia.        
The associations of higher age and male gender with the use of cardiovascular drugs confirm 
that the occurrence of CVD increases with age and men are burdened by more CVD 
compared to women. The possibility that men receive more treatment for CVD than women 
cannot be excluded. However, the gender disparity exists in particular in acute cardiac care, 
to which women may have a lower access than men157,158. On the other hand, women have 
more contact with non-acute care and are prescribed more drugs159.  
The association of slightly higher cognitive status with the use of cardiovascular drugs is 
modest, but may indicate that physicians withdraw medication in patients with more 
advanced cognitive impairment. Patients with cardiovascular drugs are less likely to live 
alone, probably because solitary living patients do not seek medical care and/or have 
difficulties with adherence to drugs160. An alternative explanation is that people who are 
healthier are able to live alone for a longer time, while those with more cardiovascular 
comorbidity may move in with relatives or to a nursing home.  
Patients with PDD and DLB were the least likely to receive cardiovascular drugs, which 
suggests a lower prevalence or less intensive treatment of CVD. The following supports 
lower prevalence of CVD in Lewy body dementias: First, while CVDs are the most common 
causes of death in the general population in Sweden as well as in the whole SveDem cohort, 
patients with Lewy body dementias are at the highest risk of dying from respiratory 
diseases161. Second, several studies report a lower burden of CVD in patients with 
Parkinson´s disease75,110,111. On the other hand, autonomic dysfunction, which is highly 
frequent in patients with Lewy body dementias, complicates the management of CVD, 
mainly hypertension, which may lead to withdrawal of cardiovascular medication124. To 
conclude, both the possibility of a lower prevalence of CVD and its less frequent treatment, 
likely explain it.  
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5.2 CHARACTERISTICS OF PATIENTS WITH HEART FAILURE AND 
DEMENTIA (PAPER II) 
 
A total number of 775 patients with heart failure and dementia were studied (mean age 82 
years, 55% of men; Table 3). The most common type of heart failure was HFPEF (38%). 
34% of patients had HFREF and 28% had missing information on ejection fraction. The most 
frequent dementia disorder was vascular dementia (36%), 28% of patients had other 
dementias, 20% mixed dementia and 16% AD. Other dementias included 186 cases 
diagnosed with unspecified dementia, 8 DLB, 6 FTD, 6 PDD and 15 with other types of 
dementia. There were no significant associations between dementia disorders and types of 
heart failure. 
 
The patients were followed for an average of 1.5 years, there were 264 deaths per 1000 
person-years. For the whole population, one-year survival rate was 76%. Individuals with 
missing information on ejection fraction had the lowest one-year survival rate (72% vs. 79% 
in HFPEF vs. 76% in HFREF), but there was no statistically significant difference (p=0.2 
from log-rank test). AD patients had the highest one-year survival rate (80% vs. 74% in 
mixed dementia vs. 75% in vascular dementia vs. 77% in other dementias), without statistical 
significance (p=0.5 from log-rank test).    
 
Table 3 Characteristics of patients with dementia and heart failure (n=775) 
Characteristic Value 
Registration to RiksSvikt in inpatient sector, n (%) 509 (65.7) 
Registration to SveDem in specialist center, n (%) 493 (63.6) 
Systolic blood pressure, mean ± SD 130.6 ± 20.6 
Heart rate, mean ± SD 74.8 ± 15.6 
MMSE, mean ± SD 21.1 ± 4.9 
Comorbidity, n (%)  
Ischemic heart disease 402 (51.9) 
Atrial fibrillation 457 (59.0) 
Diabetes mellitus 177 (22.8) 
Drugs, n (%)  
RAS antagonists 570 (73.5) 
Beta blockers 624 (80.5) 
Diuretics 614 (79.2) 
Anticoagulants 280 (36.1) 
Acetylcholinesterase inhibitors 198 (25.5) 
Memantine 66 (8.5) 
Total number of drugs 8.1 ± 3.2 
MMSE, Mini Mental State Exam; RAS, renin-angiotensin system; SD, standard deviation 
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Paper II suggests that patients with heart failure and dementia constitute an old and rather 
underdiagnosed population. The number of individuals found in both SveDem and RiksSvikt 
was low, which may be explained by the incomplete coverage of the quality registers, but 
also likely reflects down-prioritization of these patients in the health care system. A large 
proportion of patients had missing information on the level of ejection fraction, suggesting 
low diagnostic and probably therapeutic ambitions of physicians. Similarly, patients with 
unspecified dementia were highly represented, possibly due to marginal benefits expected 
from advanced diagnostic work-up.  
There were no associations between types of heart failure and dementia disorders and this 
study cannot support the role of a type of heart failure in the genesis of a specific dementia 
disorder. The most common type of heart failure was HFPEF, a syndrome that is projected to 
be the leading type of heart failure in future. Given its similarities with AD, such as strong 
correlation with age, female gender, inflammation and exposure to VRFs, HFPEF is expected 
to largely co-exist with AD85,87. We observed a trend that vascular dementia was slightly 
more common in HFREF, while AD accounted for a smaller proportion in this subgroup, 
indicating a stronger role of vascular disease in the occurrence of HFREF.  
One year survival rate of the patients was lower than in the general population of Swedish 
patients with heart failure (80%)162, possibly suggesting that dementia may contribute to 
worse prognosis of patients with heart failure. Missing information on ejection fraction may 
reflect low diagnostic ambitions, perhaps due to age, frailty and/or comorbidities, and has 
therefore been suggested as a marker of adverse outcomes163. Our study cannot support this, 
however, we observed a trend towards a higher risk of death in patients who had missing data 
on ejection fraction. The lack of significant associations may also be caused by a low sample 
size. 
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5.3 CARDIOVASCULAR COMORBIDITIES OF PATIENTS WITH DEMENTIA 
(PAPER III) 
 
In a cohort of 29 630 patients with dementia (mean age 79 years, 59% women), the most 
common CVD was ischemic heart disease (23%), followed by cerebrovascular diseases 
(20%) and atrial fibrillation (19%; Figure 11). The proportion of all CVDs was highest in 
patients with vascular dementia. The frequency of ischemic heart disease, atrial fibrillation 
and heart failure was lowest in FTD. Cerebrovascular diseases occurred least in AD and 
diabetes mellitus had the lowest frequency in PDD and DLB.   
Figure 11 Frequency of cardiovascular disease in patients with dementia 
In adjusted analysis (Figure 12), when compared to AD, diabetes mellitus was inversely 
associated with PDD (OR 0.40; 95% CI 0.27-0.59) and DLB (OR 0.59; 95% CI 0.44-0.80). 
Further, ischemic heart disease was negatively associated with PDD (OR 0.73; 95% CI 0.55-
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0.98) and FTD (OR 0.66; 95% CI 0.45-0.95). On the other hand, cerebrovascular disease was 
more likely to occur in DLB (OR 1.43; 95% CI 1.12-1.83).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 Associations of cardiovascular diseases with dementia disorders, adapted from164 
Results are derived from multinomial logistic regression and presented as OR with 95% CI 
for associations of a cardiovascular disease with dementia disorders (with Alzheimer´s 
disease as a reference), adjusted for age, gender, MMSE, living conditions, registration unit, 
total number of drugs and other cardiovascular diseases. 
OR, odds ratio; CI, confidence interval; MMSE, Mini Mental State Examination 
 
During the median follow-up of 847 days, 27% of patients died. In the whole cohort, all 
CVDs were associated with an increased risk of death. Heart failure was the strongest 
predictor of mortality (HR 1.54; 95% CI 1.44-1.65; Table 4).  
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Table 4 Associations of cardiovascular diseases with risk of death  
 HR (95% CI) 
 
Model 1 Model 2 
Ischemic heart disease 1.41 (1.34-1.48)* 1.28 (1.20-1.36)* 
Atrial fibrillation 1.69 (1.60-1.78)* 1.35 (1.27-1.44)* 
Heart failure 1.98 (1.87-2.09)* 1.54 (1.44-1.65)* 
Cerebrovascular diseases 1.40 (1.33-1.48)* 1.33 (1.25-1.41)* 
Diabetes mellitus 1.35 (1.27-1.44)* 1.45 (1.29-1.62)* 
* p<0.05 
Results are derived from Cox regression and are presented as HR with 95% CI for 
associations of cardiovascular diseases with all-cause mortality. Model 1is adjusted for age, 
gender, MMSE and type of dementia disorder. Model 2 adjusted also for living condition, 
registration unit, total number of drugs, other cardiovascular diseases and cardiovascular 
drugs. 
HR, hazard ratio; CI, confidence interval; MMSE, Mini Mental State Examination 
 
 
When stratified by dementia disorder (Figure 13), all CVDs were associated with a higher 
risk of death in AD, mixed dementia and vascular dementia. In DLB patients, only ischemic 
heart disease was associated with an increased risk of death (HR 1.72; 95% CI 1.16-2.55). In 
PDD patients, heart failure and diabetes mellitus were linked to a higher mortality risk (HR 
3.06; 95% CI 1.74-5.41 and HR 3.44; 95% CI 1.31-9.03, respectively). Ischemic heart 
disease and atrial fibrillation were predictors of death in FTD patients (HR 2.11; 95% CI 
1.08-4.14 and HR 3.15; 95% CI 1.60-6.22, respectively).  
 
In Paper III, we investigated the burden of 5 chronic CVDs in patients with dementia and 
their association with mortality. Being derived from a hospital-discharge register, that does 
not reflect the true prevalence rates; the information on CVDs may be underestimated. The 
frequency of all CVDs in our cohort is higher when compared to 70-80 years old individuals 
from a Swedish population-based study165-169, supporting the role of CVD in the genesis of 
dementia. Following prevalence of CVD is reported: 8-9% for diabetes mellitus, 15-16% for 
ischemic heart disease or cerebrovascular disease, 10% for atrial fibrillation and 10% for 
heart failure165-169. 
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All CVDs were predictors of death in the whole cohort, in accord with evidence that CVDs 
are the commonest causes of death in the general population as well as in patients with 
dementia161. Heart failure was the strongest predictor of death, which is in agreement with 
reports of its unfavorable prognosis in the elderly86,170. After stratification by dementia 
disorders, all CVDs were predictors of death in patients with AD, mixed and vascular 
dementia, while we observed different patterns in other dementia disorders.  
Figure 13 Associations of cardiovascular diseases with risk of death, adapted from164 
 
Values are derived from Cox regression and are presented as HR with 95% CI for 
associations of cardiovascular diseases with all-cause mortality, adjusted for age, gender, 
MMSE, living condition, registration unit, total number of drugs, other cardiovascular 
diseases and cardiovascular drugs. 
HR, hazard ratio; CI, confidence interval; MMSE, Mini Mental State Examination 
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Contributing to the evidence of a lower burden of CVD in Lewy body dementias110,171, we 
found a lower occurrence of diabetes mellitus in patients with DLB and PDD. A previous 
study on SveDem data showed that body mass index, a major risk factor for diabetes mellitus, 
was lowest among patients with DLB and PDD172. Despite its lower frequency, diabetes 
mellitus was a strong predictor of mortality in PDD patients. Previous studies suggested that 
diabetes mellitus in Parkinson’s disease is associated with its more severe progression and 
reduced efficacy of therapy173,174. We propose that the dysfunction of the autonomic nervous 
system, present in Parkinson’s disease as well as individuals with diabetes mellitus175, may be 
exacerbated when the two conditions co-occur, and could explain the high risk of death. Also, 
the failure to recognize symptoms of hypoglycemia due to a low sympathetic response may 
contribute to the mortality risk.  
PDD patients were also less likely to have ischemic heart disease, in line with reports that 
patients with Parkinson´s disease have fewer VRFs110. However, heart failure, even though 
not significantly associated with PDD itself, was found to be associated with an increased risk 
of death in PDD patients. There is evidence that heart failure is a common cause of death in 
Parkinson’s disease patients176. Even though the prognostic significance of the sympathetic 
denervation is not clear, autonomic dysfunction could contribute to the onset of heart 
failure48,177. Of note are also reports that some dopamine agonists used to treat Parkinson’s 
disease increase the risk of heart failure178. 
Contradicting the lower prevalence of CVD in Lewy body dementias, we observed a higher 
burden of cerebrovascular diseases in DLB patients, as in a previous study using the same 
data179. A potential explanation is that this may be caused by the use of antipsychotic drugs, 
which is considered high in DLB patients, despite their hypersensitivity to them180.  
FTD patients are burdened by fewer CVDs, which is mainly explained by their lower age. 
Even though they were least likely to suffer from ischemic heart disease, it was associated 
with a doubled risk of death in this group of patients. Moreover, atrial fibrillation was linked 
to a three times increased mortality risk. A possible explanation can be that the diagnosis of 
FTD overshadows the need for treatment of ischemic heart disease and atrial fibrillation.  
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5.4 MANAGEMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH 
DEMENTIA (PAPER IV) 
 
From the 525 patients who suffered an acute myocardial infarction after the diagnosis of 
dementia (mean age 82 years, 54% women), 86 had STEMI, 235 NSTEMI and 204 
unspecified myocardial infarction. Twenty one per cent of patients (n=110) received an 
invasive procedure for the management of myocardial infarction (coronary angiography and / 
or PCI). This was highest among STEMI patients and lowest among patients with unspecified 
myocardial infarction (Figure 14).  
 
 
 
 
 
 
 
 
 
 
 
Figure 14 Use of invasive management stratified by type of myocardial infarction 
STEMI, myocardial infarction with ST-elevation; NSTEMI, myocardial infarction without ST-
elevation 
 
Patients who received an invasive procedure were younger (78 vs. 83 years), less frequently 
women (41% vs. 57%), had a higher MMSE (24 vs. 21) and fewer comorbidities. In 
multivariate analysis (Table 5), lower age and higher MMSE were associated with receiving 
an invasive procedure, while there was no association of gender and comorbidity. Women 
had lower odds of being managed invasively in unadjusted analysis. The association became 
statistically non-significant, after controlling for type of myocardial infarction, age and 
MMSE.  
 
The patients who received an invasive procedure survived longer (p=0.001; Figure 15). The 
use of an invasive procedure was associated with a lower risk of death, after adjusting for 
type and history of acute myocardial infarction, age, gender, type of dementia disorder, 
registration unit, comorbidity score (HR 0.35; 95% CI 0.21-0.59) or total number of drugs 
(HR 0.34; 95% CI 0.20-0.58). 
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Table 5 Associations of clinical characteristics with the use of an invasive procedure 
 OR (95% CI) 
 Unadjusted Model 1 Model 2 
Age 0.89 (0.86-0.92)** 0.90 (0.86-0.94)** 0.89 (0.86-0.93)** 
Female gender 0.52 (0.34-0.79)* 0.62 (0.37-1.06) 0.69 (0.41-1.16) 
MMSE  1.18 (1.11-1.26)** 1.18 (1.10-1.26)** 1.19 (1.11-1.27)** 
Comorbidity score 0.72 (0.60-087)* 0.80 (0.63-1.00)  
Total number of drugs 0.96 (0.91-1.01)  0.97 (0.91-1.03) 
 
MMSE, Mini Mental State Examination; OR, odds ratio; CI, confidence interval 
** p˂0.001; * p<0.05; ORs with 95% CI are derived from binary logistic regression and 
are estimates for associations of clinical characteristics with the use of an invasive 
procedure. Variables in Model 1: age, gender, MMSE, comorbidity score, type of 
myocardial infarction, history of myocardial infarction. Variables in Model 2: age, gender, 
MMSE, total number of drugs, type of myocardial infarction, history of myocardial 
infarction.   
 
Figure 15 Kaplan-Meier survival curves, adapted from181 
 
In Paper IV, we used data from the Swedish Patient Register, providing information about 
hospitalization for acute myocardial infarction after the diagnosis of dementia. As in other 
dementia cohorts70,103, we found a low number of patients with myocardial infarction. 
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Patients who died out of hospital are not captured. Several cases may have not been 
recognized or registered, likely due to patients´ inability to describe symptoms, atypical 
presentation and high proportion of silent myocardial infarction182,183.  
This study suggests that the severity of cognitive impairment and higher age determine the 
management of myocardial infarction in patients with dementia. This may be explained by 
inadequate communication of symptoms, pre-hospital or in-hospital delays or personal 
judgement of physicians. In contrast with some literature157,158, this study does not indicate 
that women had a lower chance of receiving optimal treatment. There was a lower frequency 
of women receiving treatment; however, this was explained mainly by their age, cognitive 
status and type of myocardial infarction.  
The use of invasive procedures in this dementia cohort is lower than in the general 
population. Around 80% of octogenarians are treated invasively for STEMI and 20-30% for 
NSTEMI184-188. This reflects uncertainty, unknown benefits and lack of guidance to 
physicians when treating patients with dementia. Our study, investigating post-discharge 
survival of patients with dementia, suggests that patients with dementia benefit from the 
invasive management of acute myocardial infarction and supports its use in this patient 
group.  
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5.5 CARDIAC PARAMETERS IN YOUNG ADULTS AND THEIR BRAIN IN 
MID-LIFE (PAPER V) 
 
The participants (Table 6) were on average 30 years old when they underwent 
echocardiography and 50 years old when they obtained brain MRI.  
Table 6 Characteristics of the study participants (n=648) 
Characteristic Value 
          Women, n (%) 339 (52) 
          African Americans, n (%) 244 (38) 
          Years of education, mean ± SD 15.0 ± 2.3 
Cardiac parameters, mean ± SD 
          Left ventricular ejection fraction, % (n=297) 62.8 ± 7.4 
          Left atrial volume, ml/m2 (n=406) 16.1 ± 4.2 
          Left ventricular mass, g/m2 (n=627) 79.9 ± 18.4 
Brain measures, mean ± SD 
          White matter fractional anisotropy 0.3 ± 0.02 
          Gray matter volume, cm3 518.5 ± 53.7 
          White matter volume, cm3 467.0 ± 59.5 
          Total brain volume, cm3 985.5 ± 107.2 
          Abnormal white matter volume, n (%) 
                    None 127 (20) 
                    Little (≤ 0.3 cm3) 246 (38) 
                    High (> 0.3 cm3) 275 (42) 
SD, standard deviation 
 
Higher left atrial volume was significantly associated with lower white matter fractional 
anisotropy, when controlled for age, sex, race/ethnicity, field center, years of education and 
intracranial volume (Table 7). This association remained statistically significant after 
adjusting for systolic blood pressure, diastolic blood pressure, body mass index, total 
cholesterol, fasting plasma glucose, smoking status, sedentary time, alcohol intake, ApoE ε4 
allele (β -0.0023; 95% CI -0.0041; -0.0004; p=0.016). After we stratified the analysis by 
race/ethnicity, we observed the association only in African Americans. No cardiac parameter 
was associated with lower gray matter, white matter, total brain volume or higher abnormal 
white matter volume.  
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Table 7 Associations of cardiac parameters with brain measures 
 
 
White matter 
fractional anisotropy 
Gray matter 
volume 
White matter 
volume 
Total brain 
volume 
 ß (95% CI) 
LVEF -0.0003 (-0.0022; 0.0017) 
 
-0.763 
(-3.103; 1.577) 
 
1.512 
(-1.285; 4.309) 
0.749 
(-2.582; 4.079) 
 
LAV -0.0026 (-0.0044; -0.0008)* 
 
-0.042 
(-2.187; 2.103) 
 
-1.915 
(-4.444; 0.615) 
-1.957 
(-4.952; 1.039) 
 
LV mass -0.0015 (-0.0030; 0.0001) 
 
0.892 
(-1.016; 2.800) 
-0.027 
(-2.147; 2.093) 
 
0.864 
(-1.647; 3.376) 
0.50 
 Abnormal white matter volume 
 
None Little (≤ 0.3 cm3) High (> 0.3 cm3) 
 
Reference 
OR (95% CI) 
LVEF 0.94 (0.68; 1.30) 1.04 (0.74; 1.46) 
LAV 0.73 (0.54; 0.97) 0.92 (0.69; 1.22) 
LV mass 1.18 (0.92; 1.52) 1.15 (0.90; 1.49) 
 *p=0.004* 
 
LVEF, left ventricular ejection fraction; LAV, left atrial volume; LV mass, left ventricular 
mass; OR, odds ratio; CI, confidence interval 
 
ß is derived from linear regression and is a coefficient for an association of the cardiac 
parameter (independent variable) with a measure of aging brain (dependent variable). OR is 
derived from multinomial logistic regression and is a parameter for the association of the 
cardiac parameter with high or little abnormal white matter volume, when compared to no 
abnormal volume. Each cardiac parameter was transformed into Z score and entered into 
each model separately. All models are adjusted for age, sex, race/ethnicity, field center, years 
of education, intracranial volume.  
 
Paper V, based on data from a prospective longitudinal study, indicates that larger left atrium 
in young adulthood may predict impairment in white matter integrity in mid-life. This is in 
line with previous studies on older adults that reported a link between enlargement of left 
atrium and indicators of brain pathology189-191. We did not find any association of left 
ventricular ejection fraction or left ventricular mass with any MRI markers, as opposed to 
previous studies on older adults87,191-194.  
Higher left atrial volume reflects diastolic dysfunction due to the exposure to VRFs and may 
be considered an early marker of cardiac disease. It is a predictor of atrial fibrillation and 
heart failure.90,195-197 The relationship between left atrial volume and brain pathology may be 
explained by reduced brain perfusion due to lowered cardiac output or microembolism 
secondary to atrial fibrillation. 
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The data suggests an incipient impairment of white matter integrity at mid-life due to 
subclinical cardiac dysfunction. Decreased white matter integrity is possibly the first sign of 
pathological changes in the white matter, preceding development of white matter lesions, 
indicating a future risk of dementia30,31,198. Consistent with the view that prevention of 
dementia should start early in life, here we suggest that improving cardiac function in young 
adults may prevent their future brain disease. The association was strongest in African 
Americans, who have a larger burden of heart failure and dementia, when compared to 
Caucasians.84,199 We propose that African Americans may be at a higher risk of brain 
pathology due to cardiac dysfunction. 
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6 METHODOLOGICAL CONSIDERATIONS 
Generalizability of research findings is given by their internal (are the results true?) and 
external (do the results apply to other settings?) validity200. Validity is compromised by the 
presence of a systematic error – bias. There are several sources of bias, such as selection bias, 
misclassification and confounding.  
6.1 SELECTION BIAS 
Selection bias occurs when the chance that a person is included in the study is related to both 
the exposure and the outcome. It may be caused by non-participation, loss to follow-up or 
missing data. Selection bias due to non-participation is likely in Papers I-IV that are based on 
Swedish registers, which do not have a complete coverage in the country. On the other hand, 
selection bias due to loss to follow-up does not occur in Papers II-IV, where the outcome, all-
cause mortality, was identified from a nationwide register. Missing data did not appear at 
random, but in particular among older and sicker patients.  
The estimated coverage of SveDem is approximately 35%201 and of RiksSvikt around 
49%202. It has not been studied how the dementia patients in SveDem and heart failure 
patients in RiksSvikt differ from those who are not registered. As reported elsewhere203, 
patients included in a quality register are more likely to be men, younger, generally healthier 
and have a higher socioeconomic status. This biases the generalizability of the results towards 
a healthier group of patients who have more contact with health care. This may lead to 
underestimation of the cardiovascular comorbidity in participants in Papers I-IV and the 
influence of CVD on their risk of death. The effect of invasive management of acute 
myocardial infarction on the risk of death may then be overestimated.  
In order to fill in the gap in knowledge about CVD in women and minority groups, CARDIA 
study was designed to reflect the diversity in the population of the United States. At baseline, 
52% of the participants were African Americans, 40% had less than 12 years of education, 
30% reported regular smoking and the average body mass index was 24143. At the 25th 
follow-up exam, the retention was 72% from the surviving cohort; persons with more VRFs 
and African Americans were more likely to be lost to follow-up. Moreover, participants in the 
CARDIA MRI Sub-study had fewer VRFs compared to the remaining cohort. To conclude, 
this constitutes a selection bias, possible leading to underestimation of the effect of the 
cardiac parameters on brain health in Paper V.  
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6.2 MISCLASSIFICATION AND CONFOUNDING 
Misclassification appears when a variable is not appropriately measured or does not 
sufficiently capture the construct of interest. Misclassification of the diagnoses of dementia 
and CVD in Swedish registers is a concern. The clinically made dementia diagnoses used in 
Papers I-IV have not been validated by a neuropathological examination, which is considered 
a gold standard for the diagnosis of dementia. When compared to autopsy records, studies 
from other countries suggest that the clinically made diagnosis of AD is correct in around 
80% of cases204,205, this number is likely to be lower in primary care units.  
With reference to an expert review using criteria of the European Society of Cardiology, the 
validity of the diagnosis of heart failure in Sweden was suggested to be 82%. It is higher for 
patients treated in internal medicine (86%) and cardiology (91%)206. The diagnosis of acute 
myocardial infarction in the Swedish National Patient Register was suggested to have a high 
positive predictive value (98-100%)141,207 and sensitivity of 77-91%208,209. However, these 
numbers can be lower for patients with dementia, who often present with atypical symptoms, 
have problems with communication and undergo less extensive diagnostic work-up.  
A confounder is a factor associated with both the dependent and independent variable and is 
not on the causal pathway between them. An ideal way of preventing confounding is 
randomization. However, all 5 studies in this thesis are observational and there is a possibility 
that the adjustment in the analyses did not remove the effect of confounding variables, on 
which data was not collected. For example, in Papers I-IV, such factors may be lifestyle, 
genetic factors, socioeconomic and marital status, smoking, body mass index and type and 
location of the care center.      
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7 FUTURE PERSPECTIVES 
 
The life expectancy is still increasing and it does not seem that we are approaching a limit 
of human lifespan1. It would be optimal if the extending lifespan was accompanied by an 
increasing “health span”, the time lived without chronic diseases. The future will bring new 
insights into mechanisms underlying risk factors that are shared among age-related 
diseases. Possibly, we shall be able to halt the ageing process. We may stimulate 
regenerative capacity of cells, manipulate with epigenetic alterations underlying longevity, 
regulate pathways leading to autophagy and signaling cascades of senescence and 
programmed cell death.  
Until this happens, we need to improve the care of patients affected with chronic diseases. 
Non-participation of patients with dementia in randomized clinical trials leads to lacking 
knowledge about the right treatment for their comorbid CVD. Physicians face insecurity, 
generally due to lacking guidelines and unknown benefits, which results in decision making 
based on their experience and intuition, rather than on evidence. This gap in knowledge could 
be filled in with the use of advanced analytical tools that allow causal inference from 
observational data based on large nationwide registers.   
Environmental factors account for at least 70% of variation in lifespan and development of 
diseases210. Ideally, we should prevent / delay the onset of CVD and dementia, via promoting 
a healthy lifestyle starting as early in life as possible. Health inequalities related to individual 
socioeconomic position will probably be growing. Inequalities start early in life and are 
inevitable, but can be reduced by enhancing access to health care and strengthening 
educational and emotional development in order to improve health behavior211,212. The future 
needs to address complex causes of chronic diseases and find ways how to make bridges 
between their physical, biological, psychological and social aspects. 
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